The biologic antibody drug 'Nucala' is now available for prescription at tertiary general hospitals.

According to industry sources, GSK's Nucala (mepolizumab), a treatment for severe neutrophilic asthma, has passed the drug committees of the 'Big 5' tertiary hospitals, including Samsung Medical Center, Seoul University Hospital, Seoul Asan Medical Center, and Sinchon Severance Hospital, and Seoul St. Mary's Hospital.

After being listed to the reimbursement list in November, this drug is becoming more widely available in hospitals.

Nucala is an anti-interleukin (IL)-5 that reduces counts of neutrophils, a type of white blood cell contributing to asthma.

I